

Product Datasheet

ZNF24 Antibody - BSA Free

NBP1-82866

Unit Size: 0.1 ml

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Reviews: 1 Publications: 2

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP1-82866

Updated 12/2/2025 v.20.1

Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NBP1-82866



NBP1-82866


ZNF24 Antibody - BSA Free

Product Information	
Unit Size	0.1 ml
Concentration	Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.02% Sodium Azide
Isotype	IgG
Purity	Affinity purified
Buffer	PBS (pH 7.2) and 40% Glycerol
Product Description	
Description	Novus Biologicals Rabbit ZNF24 Antibody - BSA Free (NBP1-82866) is a polyclonal antibody validated for use in IHC, WB and ICC/IF. Anti-ZNF24 Antibody: Cited in 2 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Rabbit
Gene ID	7572
Gene Symbol	ZNF24
Species	Human
Reactivity Notes	Immunogen displays the following percentage of sequence identity for non-tested species: Mouse (89%)
Immunogen	This antibody was developed against Recombinant Protein corresponding to amino acids: LESELDDPGQPVSLRRRKREVLVEDMVSQEEAQGLPSSSELD AVENQLKWASW ELHSLRH CDDDGR TENGALAPKQELPSALESHEVPGT LSMGV PQIFKYGETCF PKGRFERKRNP SRKKQHICDEC GK HFS
Product Application Details	
Applications	Western Blot, Immunohistochemistry-Paraffin, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Knockdown Validated
Recommended Dilutions	Western Blot 0.04 - 0.4 ug/ml, Immunohistochemistry 1:200 - 1:500, Immunocytochemistry/ Immunofluorescence 0.25-2 ug/ml, Immunohistochemistry-Paraffin 1:200-1:500, Knockdown Validated
Application Notes	For IHC-Paraffin, HIER pH 6 retrieval is recommended. ICC/IF, Fixation Permeabilization: Use PFA/Triton X-100.




Images


Western Blot: ZNF24 Antibody [NBP1-82866] - Analysis in human cell line SCLC-21H.




Immunocytochemistry/Immunofluorescence: ZNF24 Antibody [NBP1-82866] - Immunofluorescent staining of human cell line U-251 MG shows localization to nucleus.




Immunohistochemistry-Paraffin: ZNF24 Antibody [NBP1-82866] - Staining of human lymph node shows strong cytoplasmic and nuclear positivity in subsets of cells.




Western Blot: ZNF24 Antibody [NBP1-82866] - Analysis in U2OS and HEK cells. siRNA against ZNF24 show the specificity of the antibody. ZNF24 was used 1/500 in TBST 5% milk, 1 hour at room temperature. Image submitted by a verified customer review.




Western Blot: ZNF24 Antibody [NBP1-82866] - ZNF24 promoted PD-L1 expression through binding to its promoter in FFA-treated LO2 cells. ZNF24 and PD-L1 expression in LO2 cells pretreated with siRNA against ZNF24, followed by FFA treatment detected by western blot. $P < 0.01$. PD-L1 expression was suppressed following the ZNF24 knockdown. Image collected and cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/35615575/>) licensed under a CC-BY license.




ZNF24 promoted PD-L1 expression through binding to its promoter in FFA-treated LO2 cells. (a) A schematic of the target sites (wild & mutant) of ZNF24 in the promoter of PD-L1. (b–d) Dual-luciferase reporter assays performed in LO2 cells transfected with WT or MT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression. (e–g) ZNF24 expression after FFA treatment determined by qRT-PCR & western blot. (h & i) ZNF24 expression in LO2 cells pretreated with siRNA against NOX4, MitoTEMPO (10 μ M), or NAC (5 mM) followed by FFA treatment, measured by western blot. (j & k) ZNF24 & PD-L1 expression in LO2 cells pretreated with siRNA against ZNF24, followed by FFA treatment detected by western blot. $P < 0.01$. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/35615575/>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Identification of ZNF24–UBE2I protein interactions. (a & b) Analysis of protein interactions between ZNF24 & UBE2I using the BioGRID database, further confirmed by Co-IP assays. (c–f) UBE2I expression in LO2 cells treated by FFA or pretreated with siRNA against NOX4, MitoTEMPO (10 μ M), or NAC (5 mM) followed by FFA treatment measured by western blot. (g & h) After FFA treatment, Sumo-1: ZNF24 & ZNF24 expression levels detected by western blot. (i & j) After UBE2I overexpression, Sumo-1: ZNF24, ZNF24, PD-L1, & UBE2I expression levels were determined by western blot. (k–m) Dual-luciferase reporter assays performed in LO2 cells transfected with WT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression with or without Sumo-1 overexpression. $P < 0.01$. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/35615575/>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




ROS/ZNF24/PD-L1 pathway activation in NAFLD models. (a) Intracellular ROS in hepatocytes in NAFLD significantly increased. (b) JC-1 probes were used to detect mitochondrial membrane potential. (c & d) NOX4 & ZNF24 expressions were determined by immunohistochemistry. (e & f) ROS/ZNF24/PD-L1 pathway activation examined by western blot. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/35615575/>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Western Blot: ZNF24 Antibody [NBP1-82866] - ZNF24 promoted PD-L1 expression through binding to its promoter in FFA-treated LO2 cells. (a) A schematic of the target sites (wild & mutant) of ZNF24 in the promoter of PD-L1. (b–d) Dual-luciferase reporter assays performed in LO2 cells transfected with WT or MT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression. (e–g) ZNF24 expression after FFA treatment determined by qRT-PCR & western blot. (h & i) ZNF24 expression in LO2 cells pretreated with siRNA against NOX4, MitoTEMPO (10 μ M), or NAC (5 mM) followed by FFA treatment, measured by western blot. (j & k) ZNF24 & PD-L1 expression in LO2 cells pretreated with siRNA against ZNF24, followed by FFA treatment detected by western blot. $\square\square P < 0.01$. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/35615575>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Western Blot: ZNF24 Antibody [NBP1-82866] - ZNF24 promoted PD-L1 expression through binding to its promoter in FFA-treated LO2 cells. (a) A schematic of the target sites (wild & mutant) of ZNF24 in the promoter of PD-L1. (b–d) Dual-luciferase reporter assays performed in LO2 cells transfected with WT or MT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression. (e–g) ZNF24 expression after FFA treatment determined by qRT-PCR & western blot. (h & i) ZNF24 expression in LO2 cells pretreated with siRNA against NOX4, MitoTEMPO (10 μ M), or NAC (5 mM) followed by FFA treatment, measured by western blot. (j & k) ZNF24 & PD-L1 expression in LO2 cells pretreated with siRNA against ZNF24, followed by FFA treatment detected by western blot. $\square\square P < 0.01$. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/35615575>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: ZNF24 Antibody [NBP1-82866] - Identification of ZNF24–UBE2I protein interactions. (a & b) Analysis of protein interactions between ZNF24 & UBE2I using the BioGRID database, further confirmed by Co-IP assays. (c–f) UBE2I expression in LO2 cells treated by FFA or pretreated with siRNA against NOX4, MitoTEMPO (10 μ M), or NAC (5 mM) followed by FFA treatment measured by western blot. (g & h) After FFA treatment, Sumo-1: ZNF24 & ZNF24 expression levels detected by western blot. (i & j) After UBE2I overexpression, Sumo-1: ZNF24, ZNF24, PD-L1, & UBE2I expression levels were determined by western blot. (k–m) Dual-luciferase reporter assays performed in LO2 cells transfected with WT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression with or without Sumo-1 overexpression. $\square\square P < 0.01$. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/35615575>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: ZNF24 Antibody [NBP1-82866] - Identification of ZNF24–UBE2I protein interactions. (a & b) Analysis of protein interactions between ZNF24 & UBE2I using the BioGRID database, further confirmed by Co-IP assays. (c–f) UBE2I expression in LO2 cells treated by FFA or pretreated with siRNA against NOX4, MitoTEMPO (10 μ M), or NAC (5 mM) followed by FFA treatment measured by western blot. (g & h) After FFA treatment, Sumo-1: ZNF24 & ZNF24 expression levels detected by western blot. (i & j) After UBE2I overexpression, Sumo-1: ZNF24, ZNF24, PD-L1, & UBE2I expression levels were determined by western blot. (k–m) Dual-luciferase reporter assays performed in LO2 cells transfected with WT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression with or without Sumo-1 overexpression. $P < 0.01$. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/35615575>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Dong G, Huang X, Chen R et al. Increased PD-L1 Restricts Liver Injury in Nonalcoholic Fatty Liver Disease Oxidative Medicine and Cellular Longevity 2022-05-16 [PMID: 35615575] (Western Blot, Human)

Lopez-Contreras AJ, Ruppen I, Nieto-Soler M et al. A Proteomic Characterization of Factors Enriched at Nascent DNA Molecules Cell Rep 2013-03-26 [PMID: 23545495] (WB, Human)



Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP1-82866

NBP1-82866PEP	ZNF24 Recombinant Protein Antigen
NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP1-82866

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

